CinDome Pharma, LLC Report issue

For profit Phase 2
Founded: Wilmington DE United States (2016)

Organization Overview

First Clinical Trial
2019
NCT04026997
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

CinDome Pharma, Inc. | CinDome Pharma, LLC

Active Ingredients

Drugs in Phase 2 Trials (1)

Deudomperidone (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Gastroparesis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1